Neurinnov Logo

IMPROVING
PATIENT AUTONOMY

The neurostimulation technology that resolves
unfulfilled demands in key medical conditions

Scroll down

Scroll Down

From paralysis
to movement

We are developing implantable neurostimulation solutions that enable patients living with complete tetraplegia to regain upper limb autonomy.

We are creating the first neurostimulation device that induces ‘selective’ activation of targeted muscles by steering electrical currents through one or a set of nerves.

Tomorrow, patients will be able to recover the functional use of one hand to perform everyday activities, such as grasping an object or even eating with a fork. In the future, our neurostimulation devices will be able to selectively activate any nerve target to potentially treat a variety of pathologies and deficiencies.

Successful
Early stage feasibility studies

The effectiveness of Neurinnov approach has been successfully tested on a preliminary clinical study with results published in Nature Scientific Reports Journal.

Essential
Key outcomes

Company Background

A spin-off from INRIA, the French national institute for research in digital science and technology, and the University of Montpelier, Neurinnov was founded in 2018 upon 20+ years’ research and expertise in micro-electronics, software engineering, electrophysiology and function physiology. Through its generic technology platform that adds value creation across many pathologies, Neurinnov is driving forward innovations aimed at addressing unmet needs in healthcare.

Founders

Neurinnov founders have vast expertise, culminating in decades of world-class research and development in micro-electronics, software engineering, electrophysiology and sensory-motor system, along with many years of experience leading successful medtech businesses. They have garnered several prestigious awards in research, including the “Grand prix” of the French National Academy of Sciences.

David Andreu, PhD

Co-founder, CTO and General Manager

David is a specialist in AIMD (Active Implantable Medical Device architecture, where he has won awards.

Learn more

David Guiraud, PhD

Co-founder, CSO and CEO

David is a specialist in electrophysiology and highly experienced in conducting clinical trials, including securing ethical committee approval for research.

Learn more

Latest NEWS

January 31, 2023

Neurinnov wins Grand Prize Inn’Ovations award!

We are delighted to announce that we have been awarded a €30K prize in the ‘products or services for the future’ category at the Les Inn'Ovations awards by @AD'OCC, for our implantable neurostimulator, which enables patients with complete tetraplegia to regain upper limb autonomy.

Every year, Les Inn’Ovations award recognizes some of the most innovative projects in the Occitania region of France. The awarding jury was impressed by our active implantable medical device, powered by our remotely controlled ASIC chip, which helps restore the manual grip of patients who have suffered spinal cord injury allowing them to complete everyday tasks, such as eating with a fork or drinking through a straw, giving them greater independence.

October 30, 2022

Positive results

Neurinnov has published the positive results of its clinical investigations regarding the restoration of hand control for people with high spinal cord injury in Nature Scientific Reports and Neurotrauma. Results achieved in close partnership with INRIA CAMIN, Center Bouffard-Vercelli USSAP, ORTHOSUD St Jean de Védas, CORTEC and APHP.
Click here to see the Nature Scientific Reports, 2022
Click here to see the video.

 

 

October 25, 2022

Une neuroprothèse rend l’usage de leurs mains à des tétraplégiques

Deux patients tétraplégiques ont pu retrouver un usage fonctionnel de leurs mains grâce à une nouvelle neuroprothèse, d'après des travaux publiés dans la revue Scientific Reports. Implantées au-dessus du coude et commandées par un stimulateur externe, deux électrodes leur ont permis de saisir des objets, et ainsi retrouver un peu d’autonomie pendant les 30 jours que duraient l’expérience.